文献速递妇科肿瘤

纳武利尤单抗联合伊匹木单抗治疗晚期卵巢和子宫内膜透明细胞癌:一项非随机临床试验

Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项前瞻性多中心2期非随机临床试验在17个澳大利亚和新西兰中心纳入28例晚期卵巢透明细胞癌或子宫内膜透明细胞癌患者,最多接受过1程系统治疗,给予纳武利尤单抗联合伊匹木单抗。总体客观缓解率为54%(95%CI 35-71),6个月无进展生存率为58%(95%CI 39-74),9例(35%)发生3或4级免疫相关不良事件,1例发生5级心肌炎。作者认为该方案在这类患者中显示出令人鼓舞的持久缓解活性,应进一步研究。

要点

  • 总体客观缓解率为54%(95%CI 35-71),其中完全缓解3例(12%)、部分缓解12例(42%)。
  • 卵巢透明细胞癌组客观缓解率为55%(95%CI 35-73),子宫内膜透明细胞癌组为50%(95%CI 9-91)。
  • 6个月无进展生存率为58%(95%CI 39-74),9例(35%)发生3或4级免疫相关不良事件,1例发生5级心肌炎。

核心结论

  • 作者认为,在这项非随机临床试验中,抗PD-1/CTLA-4联合阻断在晚期妇科透明细胞癌患者中显示出令人鼓舞的活性,缓解率高且持久,应在这类医疗需求未满足的患者人群中进一步研究。

研究设计与样本

  • MoST-CIRCUIT前瞻性多中心2期非随机临床试验,纳入晚期选定罕见癌症患者。
  • 纳入最多接受过1程既往系统治疗的晚期卵巢透明细胞癌或子宫内膜透明细胞癌患者,2021年8月至2024年2月入组,来自17个澳大利亚和新西兰中心。
  • 共纳入28例患者,中位(范围)年龄55(34-77)岁,其中卵巢透明细胞癌24例、子宫内膜透明细胞癌4例,19例(68%)既往接受过一程治疗。
  • 干预为纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg,每3周1次共4剂,随后纳武利尤单抗480 mg每4周1次共96周,直至疾病进展或出现不可接受的毒性。
  • 共同主要终点为按RECIST 1.1标准评估的客观缓解率和6个月无进展生存率,次要终点为中位总生存期、无进展生存期和治疗相关毒性。

主要发现

  • 总体客观缓解率为54%(95%CI 35-71),其中完全缓解3例(12%)、部分缓解12例(42%)。
  • 卵巢透明细胞癌组客观缓解率为55%(95%CI 35-73),子宫内膜透明细胞癌组为50%(95%CI 9-91)。
  • 缓解持续时间中位数未达到,所有缓解均持续中。
  • 6个月无进展生存率为58%(95%CI 39-74),中位总生存期未达到。
  • 9例(35%)发生3或4级免疫相关不良事件,1例发生5级心肌炎。

关键数值与推荐

  • 客观缓解率按RECIST 1.1标准评估,总体为54%(95%CI 35-71),卵巢透明细胞癌组55%(95%CI 35-73),子宫内膜透明细胞癌组50%(95%CI 9-91)。
  • 6个月无进展生存率为58%(95%CI 39-74)。
  • 3或4级免疫相关不良事件发生于9例(35%),5级心肌炎1例。

临床怎么用

  • 作者认为该联合方案在晚期妇科透明细胞癌患者中显示出令人鼓舞的活性,应进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gynecological clear cell cancers (CCCs) are aggressive malignant neoplasms with low response rate to chemotherapy. The treatment of patients with metastatic disease remains an area of significant unmet need. OBJECTIVE: To evaluate the efficacy of combined anti-programmed cell death 1 protein (PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade using nivolumab and ipilimumab in advanced gynecological CCCs. DESIGN, SETTING, AND PARTICIPANTS: The MoST-CIRCUIT prospective multicenter phase 2 nonrandomized clinical trial included patients with advanced selected rare cancers. Patients with advanced clear cell ovarian cancer (CCOC)/clear cell endometrial cancer (CCEC) with a maximum of 1 course of prior systemic therapy were enrolled from August 2021 to February 2024 across 17 Australian and New Zealand sites. INTERVENTIONS: Patients received nivolumab, 3 mg/kg, and ipilimumab, 1 mg/kg, every 3 weeks for 4 doses followed by nivolumab, 480 mg, every 4 weeks for 96 weeks until disease progression or the development of unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: Coprimary end points were objective response rate (ORR) and 6-month progression-free survival (PFS) as assessed by RECIST version 1.1 criteria, with the secondary end points being median overall survival, PFS, and treatment-related toxic effects. RESULTS: Of 28 included patients, the median (range) age was 55 (34-77) years. A total of 24 had CCOC and 4 had CCEC; 19 (68%) had a previous course of therapy. Overall ORR was 54% (95% CI, 35-71), with 3 (12%) with complete response and 12 (42%) with partial response; the ORR was 55% (95% CI, 35-73) in the CCOC group and 50% (95% CI, 9-91) in the CCEC group. The median duration of response has not been reached, with all responses ongoing. The 6-month PFS was 58% (95% CI, 39-74), and the median overall survival has not been reached. A total of 9 patients (35%) experienced a grade 3 or 4 immune-related adverse event, and a grade 5 myocarditis occurred in 1 patient. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, immunotherapy using combined anti-PD-1/CTLA-4 blockade demonstrated encouraging activity with a high rate of durable responses in patients with advanced gynecological CCCs. This regimen should be further investigated in this patient population with unmet medical need. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04969887.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Gao B, Carlino MS, Michael M, et al. Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40608313. doi:10.1001/jamaoncol.2025.1916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。